CCR5 (C-C chemokine receptor type 5) is a G protein-coupled receptor that binds multiple chemokines, particularly CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES). Originally characterized for its role as the major co-receptor for HIV-1 entry into host cells, CCR5 has emerged as a critical regulator of neuroinflammation, synaptic plasticity, and cognitive function in the central nervous system .
| CCR5 |
|---|
| Full Name | C-C chemokine receptor type 5 |
| Gene | CCR5 |
| UniProt ID | [P51681](https://www.uniprot.org/uniprot/P51681) |
| Protein Size | 352 amino acids |
| Protein Family | G protein-coupled receptor, chemokine receptor family |
| Chromosomal Location | 3p21.31 |
| Subcellular Location | Cell membrane, lipid rafts |
| Associated Disease | Alzheimer's Disease, Parkinson's Disease, HIV-associated neurocognitive disorder |
CCR5 is a seven-transmembrane G protein-coupled receptor (GPCR) with the following structural features:
- N-terminal extracellular domain: Contains glycosylation sites and contributes to ligand binding specificity
- Extracellular loops (ECL1-3): Form the ligand-binding pocket for chemokines
- Transmembrane domains (TM1-7): Spanning the cell membrane, connecting to intracellular signaling
- Intracellular loops (ICL1-3): Couple to G proteins and β-arrestin
- C-terminal intracellular tail: Contains serine/threonine residues for phosphorylation and regulation
- Δ32 mutation: A 32-base pair deletion in the CCR5 gene (CCR5-Δ32) creates a non-functional receptor, providing natural resistance to HIV infection in homozygotes. This mutation has been associated with altered disease risk in neurodegenerative conditions .
- Ligand binding: CCR5 can bind multiple chemokines with different affinities, enabling context-dependent signaling.
- Dimerization: CCR5 can form homodimers and heterodimers with other chemokine receptors, modulating its function.
In the central nervous system, CCR5 is expressed on multiple cell types:
- Microglia: The primary immune cells of the brain, expressing high levels of CCR5
- Neurons: Express CCR5 at lower levels, where it modulates synaptic activity
- Astrocytes: Can express CCR5 in response to inflammatory signals
- Endothelial cells: CCR5 regulates leukocyte trafficking across the blood-brain barrier
CCR5 activates multiple intracellular signaling cascades:
- Gαi signaling: Inhibits adenylate cyclase, reducing cAMP levels
- MAPK pathways: Activates ERK1/2, p38, and JNK
- PI3K/Akt pathway: Promotes cell survival signals
- NF-κB activation: Induces inflammatory gene expression
- Neuroinflammation regulation: Controls microglial activation and cytokine production
- Synaptic plasticity: Modulates long-term potentiation (LTP) and memory formation
- Neurogenesis: Influences adult hippocampal neurogenesis
- Cell migration: Guides immune cell recruitment to sites of injury or infection
CCR5 plays a dual role in Alzheimer's disease neuroinflammation :
- Pro-inflammatory effects: CCR5 activation on microglia promotes production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), contributing to chronic neuroinflammation.
- Aβ clearance: CCR5 signaling modulates microglial phagocytosis of amyloid-beta plaques .
- Neurotoxicity: Excessive CCR5 signaling can lead to excitotoxicity and neuronal death.
Multiple studies have investigated CCR5 genetic variants in AD risk:
- Promoter polymorphisms: Certain CCR5 promoter variants have been associated with altered AD risk in specific populations .
- Δ32 mutation: The protective CCR5-Δ32 variant has shown inconsistent associations with AD risk, with some studies suggesting protection and others showing no effect .
- Clinical outcomes: CCR5 genetic variants may influence disease progression and clinical outcomes in AD patients .
CCR5 antagonists have shown promise in AD models:
- Maraviroc: The FDA-approved HIV drug has demonstrated neuroprotective effects in preclinical AD models .
- Mechanism: Blocking CCR5 reduces microglial activation, decreases neuroinflammation, and improves memory deficits.
- Tau pathology: CCR5 antagonists may reduce tau pathology through modulation of inflammatory pathways .
Several studies have linked CCR5 genetic variants to PD risk and progression:
- PD risk: Certain CCR5 haplotypes have been associated with altered PD susceptibility .
- Disease progression: CCR5 genetic variants may influence motor and non-motor symptom progression .
- Expression studies: Increased CCR5 expression has been observed in PD patient brains .
CCR5 contributes to PD-related neuroinflammation through multiple mechanisms:
- Microglial activation: CCR5 mediates microglial recruitment and activation in the substantia nigra.
- Dopaminergic neuron toxicity: CCR5 signaling promotes inflammatory responses that damage dopaminergic neurons.
- α-Synuclein interaction: CCR5 may influence α-synuclein aggregation and toxicity .
Targeting CCR5 in PD shows therapeutic potential:
- Neuroprotection: CCR5 blockade protects dopaminergic neurons from inflammation-induced death .
- Motor improvement: CCR5 antagonists may improve motor symptoms in PD models.
- Combination therapy: CCR5 targeting may complement other neuroprotective strategies.
¶ CCR5 and Aging
CCR5 expression increases with age and contributes to age-related cognitive decline :
- Memory impairment: Elevated CCR5 signaling impairs hippocampal synaptic plasticity and memory.
- Neurogenesis decline: CCR5 modulates age-related decreases in adult neurogenesis.
- Inflammatory aging: CCR5 contributes to chronic low-grade inflammation characteristic of aging.
- CCR5 antagonists: Show promise in reversing age-related cognitive decline.
- Lifestyle factors: Exercise and caloric restriction may modulate CCR5 expression.
| Agent |
Status |
Mechanism |
Indication |
| Maraviroc |
Approved (HIV), Investigational (AD) |
CCR5 antagonist |
HIV, AD |
| Vicriviroc |
Clinical trials |
CCR5 antagonist |
HIV, AD |
| CCR5-targeting antibodies |
Preclinical |
Neutralizing antibodies |
AD, PD |
| Gene therapy |
Preclinical |
RNA interference |
PD |
- Blood-brain barrier: Drug delivery to the CNS remains challenging
- Cell-type specificity: Targeting CCR5 on specific cell types (microglia vs neurons)
- Dose optimization: Balancing anti-inflammatory effects with immune competence
- Cell-type specific functions: How CCR5 function differs across cell types in the brain
- Downstream signaling: Precise molecular pathways mediating CCR5 effects in neurons
- Therapeutic window: Optimal timing and duration of CCR5-targeted interventions
- Clinical trials: Evaluating CCR5 antagonists in AD and PD patients
- Biomarkers: Identifying CCR5-related biomarkers for disease monitoring
- Combination approaches: CCR5 targeting combined with other neuroprotective strategies